Mutations in the TFs ERG and ETV6 and the histone demethylase complex subunit ARID5B, previously linked to poor treatment outcomes in ALL [46, 78], were prevalent in EOI slow responders, while mutations in IKZF2 and the histone H3K79 methyltransferase DOT1L were enriched in fast responders. This evidence concerns the gene ERG and acute lymphoblastic leukemia.